Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Biopharma Files China IND for I-O Multiple Myeloma Treatment

publication date: Aug 8, 2018

Shanghai's I-Mab BioPharma has submitted an IND in China for approval to conduct clinical trials of its immuno-oncology multiple myeloma treatment. TJ202/MOR202 is a mAb that is directed against CD38, activating the immune system's killer cells. One year ago, I-Mab in-licensed China rights to the candidate from Germany's MorphoSys in a $120 million agreement. MorphoSys has started Phase II trials of the drug in Germany and Austria. More details....

Stock Symbols: (FSE: MOR; NSDQ: MOR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.